Update on the authors guideline in Medical Journal of Indonesia


Updates on Clinical Trial Registry
In line with the Declaration of Helsinki and to avoid selective publication, all clinical trials (phase I to IV) submitted to Medical Journal of Indonesia must be registered to the publicly accessible registration in any registry as recommended by the ICMJE. All manuscripts (clinical trial) submitted after July 2021 without any registration will not be furtherly processed for review.

In accordance with the ICMJE, the acceptable registries are:

  • www.clinicaltrials.gov
  • www.anzctr.org.au
  • www.ISRCTN.org
  • www.umin.ac.jp/ctr/index/htm
  • www.trialregister.nl
  • https://eudract.ema.europa.eu/
  • and all registries that fulfill the criteria as stated in the WHO International Clinical Trials Registry Platform (https://www.who.int/clinical-trials-registry-platform/network)


Updates on Systematic Review and Meta-Analysis Registry
We also encourage the authors to register the systematic review and meta-analysis in the PROSPERO (https://www.crd.york.ac.uk/prospero/) to help avoid unplanned duplication and reduce the opportunity for reporting bias. Starting July 2021, the authors who submit unregistered manuscripts should provide the reasons along with the cover letter for editorial consideration.